Context: In some patients symptoms of hypothyroidism persist despite therapy with T 4 .
COMMENT
The routine use of computerized "search engines" and availability of computerized tools for comparing therapeutic trials constitutes one of the bases of evidencebased medicine and, in this approach, meta-analyses have become a mainstay in medical clinical research. At almost every international thyroid congress, we hear new data on hypothyroid patients who don't feel well under "adequate" T 4 treatment and also new results on the potential advantage of combining T 3 with T 4 for this long term treatment. Thyroxine is the logical treatment of hypothyroidism for the following main reasons: 1) physiologically, the thyroid gland produces essentially T 4 (and little T 3 ); 2) T 4 has a long half life (~1 week), hence providing stable quantities of T 3 by peripheral -intracellular -regulation of T 3 production through the progressive deioidination of T 4 ; 3) there is a logdecimal inverse correlation between serum TSH and free T 4 levels (that does not exist with free T 3 ); and finally 4) the administration of T 3 induces peaks of high serum T 3 levels in the hours following its administration and, therefore, steady-state levels cannot be achieved with this hormone when given once a day.
The authors undertook a systematic search of potentially relevant publications (N = 503). Of this large database, 490 publications were excluded because they were not randomized controlled trials (RCT). Of the 13 publications retrieved for further detailed evaluation, 2 others were excluded (1 because of insufficient data and 1 because of 'double' publication).
Finally, they were left with 11 RCT that met the eligibility criteria for metaanalysis, corresponding to a total of over 1.000 patients. These studies are relatively recent, published from 1999 (Bunevicius) until 2005 (Appelhof; Escobar-Morreale; Rodriguez; Saravanan). The main result of the present analysis was that T 3 -T 4 combination therapy used as replacement therapy for patients treated for hypothyroidism provided no advantage when compared with the standard monotherapy using T 4 . There was no benefit in terms of symptoms (fatigue, bodily pain, anxiety, depression) and no improvement in the quality of life. Moreover, the combination therapy led to no improvement in cognitive efficiency or the ability to undertake novel tasks, memory, attention, etc. Finally, lipid profile was not improved in patients prescribed the combination treatment. It should also be mentioned that the trials varied in the doses of T 3 given as well as duration of treatment. However and despite these differences, the primary outcomes did not depend on T 3 dose or duration of prescription. My only personal addition to this excellent study is that with the only commercial T 3 -T 4 combination therapy available in our country, we are often referred patients who present cardiac or arrhythmic detrimental side effects associated with high serum T 3 levels. 
